Search
Arizona Paid Clinical Trials
A listing of 1656 clinical trials in Arizona actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1549 - 1560 of 1656
Arizona is currently home to 1656 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Phoenix, Tucson, Scottsdale and Mesa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Study to Evaluate Visually Inspired Patient Education Material on Willingness to Pursue Radiation Therapy
Recruiting
This research study is being done in order to better understand and identify American Indian/Alaskan Native (AI/AN) cancer patients' attitudes and beliefs towards radiation therapy treatment plans and their willingness to pursue them.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: Mayo Clinic in Arizona, Phoenix, Arizona
Conditions: Patient Education in Radiation Oncology
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
Recruiting
This study evaluates the effect of bladder cancer treatment on quality of life.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium
Recruiting
The objective is to evaluate the safety and efficacy of low dose and high dose CBT-001 eye drop dosed twice daily for 24 months compared to vehicle in reducing conjunctival hyperemia and preventing pterygium progression in eyes with pterygia.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/29/2024
Locations: Cornea and Cataract Consultants of Arizona, Phoenix, Arizona
Conditions: Pterygium
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
Recruiting
This phase II trial studies the effect of the combination of ramucirumab and trifluridine/tipiracil or paclitaxel in treating patients with previously treated gastric or gastroesophageal junction cancer that has spread to other places in the body (advanced). Ramucirumab may damage tumor cells by targeting new blood vessel formation. Trifluridine/tipiracil is a chemotherapy pill and that may damage tumor cells by damaging their deoxyribonucleic acid (DNA). Paclitaxel may block cell growth by stop... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/29/2024
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Unresectable Gastric Adenocarcinoma, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization
Recruiting
Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints.
Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).
Gender:
ALL
Ages:
21 years and above
Trial Updated:
03/28/2024
Locations: University of Arizona, Tucson, Arizona
Conditions: AAA, AAA - Abdominal Aortic Aneurysm
CERAMENT™| Bone Void Filler Device Registry
Recruiting
A device registry to compile data on the performance of CERAMENT BONE VOID FILLER in normal use.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: HonorHealth, Scottsdale, Arizona
Conditions: Orthopedic Disorder
Registry of Arthrex Hand and Wrist Products
Recruiting
A Multi-Center, Prospective Registry to Evaluate the Continued Safety and Effectiveness of Hand and Wrist Products
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: MORE Foundation, Phoenix, Arizona
Conditions: Ulnar/Radial Collateral Ligament Reconstruction, Ligament Repair or Reconstruction, Small Bone Fragments and Arthrodesis, Scapholunate Ligament Reconstruction, Carpal Fusion (Arthrodesis) of the Hand, Digital Tendon Transfers, Carpometacarpal Joint Arthroplasty
Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers
Recruiting
To compare the efficacy of XDEMVY ophthalmic drop to its vehicle control for the treatment of Demodex blepharitis and its impact on the soft contact lens wearing experience.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/22/2024
Locations: Site, Cave Creek, Arizona
Conditions: Demodex Blepharitis
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
Recruiting
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Arizona Liver Health - Chandler, Chandler, Arizona
Conditions: NASH, Cirrhosis, Liver
SportsPro: Post-Market Clinical Follow Up Study
Recruiting
Retrospective, multi-center, chart review (only to include data that is part of the surgeons' standard practice)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: Musculoskeletal-Orthopedic Research and Education Foundation, Phoenix, Arizona
Conditions: Shoulder Injuries, Knee Injuries, Hip Injuries
Gentamicin Bladder Instillation on CAUTI
Recruiting
Urinary tract infections in catheterized patients is an unacceptable complication and has been termed a 'never event' by the Center for Medicare \& Medicaid Services (CMS); however there is not consensus among clinicians on how to best prevent CAUTIs. We propose a prospective randomized controlled trial to test the efficacy of prophylactic gentamicin bladder irrigation in elimination of CAUTIs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: St. Jpseph's Hospital and Medical Center, Phoenix, Arizona
Conditions: Catheter Infection
e-HERO: Ending the HIV Epidemic in Rural Oklahoma
Recruiting
The goal of this study is to increase HIV and syphilis testing and linkage to care, increase condom use, and promote PrEP uptake among sexual minority men (SMM) and American Indian (AI) men in rural Oklahoma, a state that is an Ending the HIV Epidemic (EHE) priority state. The proposed supplement aims to: refine our preliminary intervention strategy in partnership with a Community Advisory Board (CAB) and rural peer mentors, and to assess feasibility, acceptability, and preliminary impact of the... Read More
Gender:
MALE
Ages:
Between 17 years and 29 years
Trial Updated:
03/19/2024
Locations: Northern Arizona University, Flagstaff, Arizona
Conditions: Human Immunodeficiency Virus (HIV)